CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies
about
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targetsTGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancersMolecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and diseaseCpG island methylation in colorectal cancer: past, present and futureEpigenetics of colorectal cancerMolecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary fieldThe significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patientsSerrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapyColorectal Cancer Biomarkers: Where Are We Now?Towards the introduction of the 'Immunoscore' in the classification of malignant tumoursHIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectumA genome-wide DNA methylation study in colorectal carcinoma.18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells.Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sampleDistinct high-profile methylated genes in colorectal cancerAberrant gene promoter methylation associated with sporadic multiple colorectal cancerComprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features.The CpG island methylator phenotype (CIMP) in colorectal cancer.Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancerUtility of p16 immunohistochemistry for the identification of Lynch syndromePTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiencyDNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancerA cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis.Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP).Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reactionEpigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome.MSH6 G39E polymorphism and CpG island methylator phenotype in colon cancerB vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP).The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases.NRAS mutations are rare in colorectal cancer.Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies.Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer.
P2860
Q21245727-01D80CEF-E277-4C72-B605-9A78006291C7Q24288715-6C0716E7-52CD-4A5D-B37A-92344A36FE62Q24289344-9E382E2D-6E7B-41EA-8519-440E1E549902Q24597977-53614F11-4EE2-419C-9C39-97C26BC3B8FDQ24598045-610A4DFB-6EE8-4081-BD1C-7762CB20C5FBQ24620628-A0502DBE-972F-4C9E-9415-B82E623A39B0Q26738665-974215CF-85F8-45EC-B143-A3739C79653EQ26751035-D30F943B-733C-4375-9F4C-8A0B46A2D045Q27003134-E59AC631-90F5-48CB-93D5-FAFDCCF5E59EQ27026489-A8FA05CB-9429-497C-8E32-67B33C0EAFD4Q27851557-E11B5AC0-6DCF-4C34-83CF-7E5CF927B282Q28209990-7F83FCAF-787D-4A42-A4A9-FA9EACF2966CQ28262150-3A697B8C-3683-4AFA-845E-78F02DEBC3FBQ31020320-F732548F-85CA-44DE-89D9-830257A1F48AQ33283458-F49ED636-DA53-4224-A720-5D29A491D9BEQ33301019-0DD5DC9C-E9EF-44D3-9E76-F98E706A0F05Q33326627-546425AB-1A26-4F52-8FA9-9C16C0F85560Q33383866-828D6AC3-5F80-46A4-8D5B-E8C8F4B6995AQ33502762-7EA3C8C4-F41B-4309-931D-9F33CDE2D7E3Q33526369-61687A4E-E812-4346-83A7-D77149737F3BQ33584274-576D50FD-BBAC-440C-9AC8-D01E90CA3181Q33596629-264A2BFD-4D75-42E5-AA2E-7905C3FF8981Q33611481-9314B6D4-2112-4E37-BA18-FE966FF47EB7Q33675252-BE520FA2-6DC5-4371-8F45-19DA11D0C25EQ33723499-3B1A469B-34E0-4DA2-B470-50A719C3BA39Q33808550-97109AAA-70F5-4F83-A536-7E474678C75AQ33811768-8481D7C1-1CD3-4EF0-8AD9-4CB6CD1471D0Q33837632-4B0B27C8-DE53-40D8-8A25-38DAF4CE4E21Q33837712-975A9B47-84B0-4E78-9B8A-A1F58EF1337CQ33869180-616CE6D4-9946-4931-98A3-8A53CA71EF67Q33883829-20F6AE10-42FD-42B5-89AE-97984DA0C5EEQ33942280-614C60AB-CC08-4EA5-AECA-F0635E03B1E0Q33947093-4947440F-B429-46FA-82D8-4FD5E9559D8FQ33954544-47777642-B6D2-4B57-B9C8-755AA7DA1D53Q33954696-6FE0F1A0-B467-4D64-9CB0-54F657145F70Q33986683-861243B6-5759-47CB-B055-D98420DE33BFQ34066685-45AF412F-4374-41AA-9484-3BCE3F5D55B3Q34091172-D2D49D7E-DFA8-433D-9DDE-F6FBDCE9A301Q34234728-50D98071-38E0-49B1-8A73-E0F0942F4E76Q34250109-06EC1D87-E485-4043-8AF6-C1FFB2BD4E40
P2860
CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
CpG island methylator phenotyp ...... and prospective cohort studies
@ast
CpG island methylator phenotyp ...... and prospective cohort studies
@en
type
label
CpG island methylator phenotyp ...... and prospective cohort studies
@ast
CpG island methylator phenotyp ...... and prospective cohort studies
@en
prefLabel
CpG island methylator phenotyp ...... and prospective cohort studies
@ast
CpG island methylator phenotyp ...... and prospective cohort studies
@en
P2093
P2860
P356
P1433
P1476
CpG island methylator phenotyp ...... and prospective cohort studies
@en
P2093
D J Weisenberger
G J Kirkner
M Brahmandam
T Kawasaki
P2860
P304
P356
10.1136/GUT.2005.082933
P407
P50
P577
2006-01-11T00:00:00Z